nect Biopharma (US:CNTB) Globenewswire·2024-05-07 10:30Core Insights - Connect Biopharma announced that data from its global Phase 2b trial of rademikibart for moderate-to-severe asthma has been accepted for presentation at the ATS 2024 International Meeting [1] - The company focuses on developing therapies for chronic inflammatory diseases through T cell-driven research [1][3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases [3] - The company is developing innovative therapies, including rademikibart, which targets interleukin-4 receptor alpha (IL-4Rα) for treating atopic dermatitis and asthma [3] - Another product candidate, icanbelimod, is in development for ulcerative colitis [3] Presentation Details - The poster presentation titled "Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma" will be presented by Dr. Edward Kerwin [2] - The session is scheduled for May 22, 2024, at the San Diego Convention Center [2]